ArticleTransfusion2025
Contemporary use and safety of prepartum autologous blood donation: A retrospective cohort study in Quebec, Canada.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAutologous blood donation (ABD) can be indicated in pregnant individuals with rare blood groups. Yet, unlike hospitals, some blood establishments are reluctant to collect ABDs in this population. Therefore, we evaluated the safety and use of prepartum ABD conducted by a blood establishment. STUDY DESIGN AND
methodsThis retrospective, descriptive cohort study used data from the ABD program in Québec, Canada, and patient medical data reported by treating physicians. Patients were included if they were pregnant, enrolled in Québec's ABD program between January 2010 and January 2021 (i.e., study period) and had a rare blood group.
resultsTwenty-four individuals met the inclusion criteria (mean age at first referral = 31.7 years; 21 [87.5%] first-time donors) and initiated 52 ABDs. Three mild vasovagal reactions (VVRs) were recorded, while no moderate or severe vasovagal reactions (VVRs) were observed. Of the 41 units distributed to the hospitals' blood banks, none were transfused to the mother; 3 were transfused to the fetus or newborn. Most fresh unused units were salvaged and cryopreserved post-delivery (75.0%). Twenty-seven (51.9%) ABDs were made <3 weeks of the expected date of delivery. All seven individuals with available data on iron supplementation had iron deficiency, but only two (28.6%) received intravenous iron. DISCUSSION: ABDs may be safely carried out by a blood establishment among pregnant individuals. Transfusion rate is low; however, the majority of donated units are successfully recovered. Improvements will be made to the program by developing specific guidance to target iron deficiency management and timing of donation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.